Retinal and ocular toxicity in ocular application of drugs and chemicals - Part II: Retinal toxicity of current and new drugs

Ophthalmic Research

Volumn 44, Issue 4, 2010, Pages 205-224

  Penha, Fernando Marcondes ^a,b   Rodrigues, Eduardo B ^a   Maia, Maurício ^a   Furlani, Bruno A ^a   Regatieri, Caio ^a   Melo, Gustavo B ^a   Magalhães Jr , Octaviano ^a   Manzano, Roberta ^a   Farah, Michel E ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Emílio Fernandes Schoroeder ^*  (Brazil)

Author keywords

Antimetabolites; Avastin; Bevacizumab; Corticosteroids; Lucentis; Microplasmin; Monoclonal antibodies; Nonsteroidal anti inflammatory drugs; Ranibizumab; Retina; Triamcinolone; Tumor necrosis factor; Vascular endothelial growth factor

Indexed keywords

ACICLOVIR; AMIKACIN; ANTIFUNGAL AGENT; BEVACIZUMAB; CEFTAZIDIME; CIPROFLOXACIN; COLCHICINE; DEXAMETHASONE; FIBRINOLYTIC AGENT; FLUOCINOLONE ACETONIDE; FLUOROURACIL; FOSCARNET SODIUM; GANCICLOVIR; GATIFLOXACIN; GENTAMICIN; KANAMYCIN; METHOTREXATE; MOXIFLOXACIN; NETILMICIN; OFLOXACIN; PEFLOXACIN; RANIBIZUMAB; TOBRAMYCIN; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; TRIESENCE; TRIVARIS; TROVAFLOXACIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR; VANCOMYCIN; VINCRISTINE;

ANIMAL CELL CULTURE; ANTIBIOTIC PROPHYLAXIS; BIOCOMPATIBILITY; CATARACT; CORNEA EPITHELIOPATHY; CORNEA INJURY; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS INFECTION; CYTOMEGALOVIRUS RETINITIS; CYTOTOXICITY; DIABETIC RETINOPATHY; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; ENDOPHTHALMITIS; EXPERIMENTAL RABBIT; EYE INFECTION; EYE INFLAMMATION; EYE TOXICITY; EYE TUMOR; FUNGAL ENDOPHTHALMITIS; GLAUCOMA; HUMAN; HUMAN CELL CULTURE; LOW DRUG DOSE; LYMPHOMA; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; NONHUMAN; OSMOLARITY; PH; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA CELL; RETINA INJURY; RETINA MACULOPATHY; RETINA NERVE CELL; RETINA VEIN OCCLUSION; RETINAL TOXICITY; REVIEW; SINGLE DRUG DOSE; UVEITIS;

ANIMALS; DRUG EVALUATION, PRECLINICAL; DRUG TOXICITY; HUMANS; MODELS, ANIMAL; RETINA; RETINAL DISEASES; TOXICITY TESTS;

EID: 77955292510     PISSN: 00303747     EISSN: None     Source Type: Journal    
DOI: 10.1159/000316695     Document Type: Review

References (146)

1. Bourges JL, Gautier SE, Delie F, Bejjani RA, Jeanny JC, Gurny R, Ben Ezra D, Behar-Cohen FF: Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Ophthalmol Vis Sci 2003; 44: 3562-3569.
2. Clark AF, Yorio T: Ophthalmic drug discovery. Nat Rev Drug Discov 2003; 2: 448-459.
3. Ziche M, Donnini S, Morbidelli L: Development of new drugs in angiogenesis. Curr Drug Targets 2004; 5: 485-493.
4. Bhatnagar P, Spaide RF, Takahashi BS, Peragallo JH, Freund KB, Klancnik JM Jr, Cooney MJ, Slakter JS, Sorenson JA, Yannuzzi LA: Ranibizumab for treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2007; 27: 846-850.
5. Blick SK, Keating GM, Wagstaff AJ: Ranibizumab. Drugs 2007; 67: 1199-1206, discussion 1207-1199.
6. Novack GD: Pharmacotherapy for the treatment of choroidal neovascularization due to age-related macular degeneration. Annu Rev Pharmacol Toxicol 2008; 48: 61-78.
7. Vavvas D, D Amico DJ: Pegaptanib (Macugen): treating neovascular age-related macular degeneration and current role in clinical practice. Ophthalmol Clin North Am 2006; 19: 353-360.
8. Ohm J: Über die Behandlung der Netzhautablösung durch operative Entleerung der subretinalen Flüssigkeit und Einspritzung von Luft in den Glaskörper. Graefes Arch Clin Exp Ophthalmol 1911; 79: 442-450.
9. Friedman AH, Orellana J, Freeman WR, Luntz MH, Starr MB, Tapper ML, Spigland I, Roterdam H, Mesa Tejada R, Braunhut S, Mildvan D, Mathur U: Cytomegalovirus retinitis: a manifestation of the acquired immune deficiency syndrome (AIDS). Br J Ophthalmol 1983; 67: 372-380.
10. Blankenship GW: Evaluation of a single intravitreal injection of 5-fluorouracil in vitrectomy cases. Graefes Arch Clin Exp Ophthalmol 1989; 227: 565-568.
11. Vander JF: Tissue plasminogen activator irrigation to facilitate removal of subretinal hemorrhage during vitrectomy. Ophthalmic Surg 1992; 23: 361-363.
12. Jaffe GJ, Yang CH, Guo H, Denny JP, Lima C, Ashton P: Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci 2000; 41: 3569-3575.
13. Holekamp NM, Thomas MA, Pearson A: The safety profile of long-term, high-dose intraocular corticosteroid delivery. Am J Ophthalmol 2005; 139: 421-428.
14. Kwak HW, D Amico DJ: Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol 1992; 110: 259-266.
15. Yu SY, Damico FM, Viola F, D Amico DJ, Young LH: Retinal toxicity of intravitreal triamcinolone acetonide: a morphological study. Retina 2006; 26: 531-536.
16. Ishibashi T, Miki K, Sorgente N, Patterson R, Ryan SJ: Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol 1985; 103: 708-711.
17. Maia M, Farah ME, Belfort RN, Penha FM, Lima Filho AA, Aggio FB, Belfort R Jr: Effects of intravitreal triamcinolone acetonide injection with and without preservative. Br J Ophthalmol 2007; 91: 1122-1124.
18. Dyer D, Callanan D, Bochow T, Abraham P, Lambert HM, Lee SY, Schneiderman T, Potts SL, Walker TM: Clinical evaluation of the safety and efficacy of preservative-free triamcinolone (Triesence [triamcinolone acetonide injectable suspension] 40 mg/ml) for visualization during pars plana vitrectomy. Retina 2009; 29: 38-45.
19. Moshfeghi AA, Nugent AK, Nomoto H, Sanislo SR, Kitchens JW, Moshfeghi DM: Triamcinolone acetonide preparations: impact of crystal size on in vitro behavior. Retina 2009; 29: 689-698.
20. Hancock HA, Guidry C, Read RW, Ready EL, Kraft TW: Acute aminoglycoside retinal toxicity in vivo and in vitro. Invest Ophthalmol Vis Sci 2005; 46: 4804-4808.
21. Oum BS, D Amico DJ, Kwak HW, Wong KW: Intravitreal antibiotic therapy with vancomycin and aminoglycoside: examination of the retinal toxicity of repetitive injections after vitreous and lens surgery. Graefes Arch Clin Exp Ophthalmol 1992; 230: 56-61.
22. D Amico DJ, Caspers-Velu L, Libert J, Shanks E, Schrooyen M, Hanninen LA, Kenyon KR: Comparative toxicity of intravitreal aminoglycoside antibiotics. Am J Ophthalmol 1985; 100: 264-275.
23. Almeida LN, Canedo MG, Almeida RN, Almeida Sobrinho EF, Nehemy MB: Macular infarction after intravitreal injection of amikacin: case report. Arq Bras Oftalmol 2005; 68: 837-840.
24. Campochiaro PA, Green WR: Toxicity of intravitreous ceftazidime in primate retina. Arch Ophthalmol 1992; 110: 1625-1629.
25. Borhani H, Peyman GA, Wafapoor H: Use of vancomycin in vitrectomy infusion solution and evaluation of retinal toxicity. Int Ophthalmol 1993; 17: 85-88.
26. Hegazy HM, Kivilcim M, Peyman GA, Unal MH, Liang C, Molinari LC, Kazi AA: Evaluation of toxicity of intravitreal ceftazidime, vancomycin, and ganciclovir in a silicone oil-filled eye. Retina 1999; 19: 553-557.
27. Zimmer-Galler IE, Santos A, Haller JA, Campochiaro PA: Management of endophthalmitis in a silicone oil-filled eye. Retina 1997; 17: 507-509.
28. Wiechens B, Grammer JB, Johannsen U, Pleyer U, Hedderich J, Duncker GI: Experimental intravitreal application of ciprofloxacin in rabbits. Ophthalmologica 1999; 213: 120-128.
29. Kernt M, Neubauer AS, Ulbig MW, Kampik A, Welge-Lussen U: In vitro safety of intravitreal moxifloxacin for endophthalmitis treatment. J Cataract Refract Surg 2008; 34: 480-488.
30. Aydin E, Kazi AA, Peyman GA, Esfahani MR: Intravitreal toxicity of moxifloxacin. Retina 2006; 26: 187-190.
31. Thompson AM: Ocular toxicity of fluoroquinolones. Clin Exp Ophthalmol 2007; 35: 566-577.
32. Khan FA, Slain D, Khakoo RA: Candida endophthalmitis: focus on current and future antifungal treatment options. Pharmacotherapy 2007; 27: 1711-1721.
33. Mochizuki K, Yamashita Y, Torisaki T, Komatsu K, Tanahashi T, Sakai H: Intraocular penetration and effect on the retina of fluconazole. Lens Eye Toxic Res 1992; 9: 537-546.
34. Cheng CK, Yang CH, Hsueh PR, Liu CM, Lu HY: Vitrectomy with fluconazole infusion: retinal toxicity, pharmacokinetics, and efficacy in the treatment of experimental candidal endophthalmitis. J Ocul Pharmacol Ther 2004; 20: 430-438.
35. Hariprasad SM, Mieler WF, Lin TK, Sponsel WE, Graybill JR: Voriconazole in the treatment of fungal eye infections: a review of current literature. Br J Ophthalmol 2008; 92: 871-878.
36. Gao H, Pennesi M, Shah K, Qiao X, Hariprasad SM, Mieler WF, Wu SM, Holz ER: Safety of intravitreal voriconazole: electroretinographic and histopathologic studies. Trans Am Ophthalmol Soc 2003; 101: 183-189, discussion 189.
37. Sen P, Gopal L, Sen PR: Intravitreal voriconazole for drug-resistant fungal endophthalmitis: case series. Retina 2006; 26: 935-939.
38. Saran BR, Maguire AM: Retinal toxicity of high dose intravitreal ganciclovir. Retina 1994; 14: 248-252.
39. Arevalo JF, Garcia RA, Mendoza AJ: Highdose (5,000-microg) intravitreal ganciclovir combined with highly active antiretroviral therapy for cytomegalovirus retinitis in HIV-infected patients in Venezuela. Eur J Ophthalmol 2005; 15: 610-618.
40. Ausayakhun S, Watananikorn S, Ngamtiphakorn S, Prasitsilp J: Intravitreal foscarnet for cytomegalovirus retinitis in patients with AIDS. J Med Assoc Thai 2005; 88: 103-107. (Pubitemid 40824420)
41. Ló;pez-Cortés LF, Pastor-Ramos MT, Ruiz- Valderas R, Cordero E, Uceda-Montañés A, Claro-Cala CM, Lucero-Muñoz MJ: Intravitreal pharmacokinetics and retinal concentrations of ganciclovir and foscarnet after intravitreal administration in rabbits. Invest Ophthalmol Vis Sci 2001; 42: 1024-1028.
42. De Smet MD, Meenken CJ, van den Horn GJ: Fomivirsen - a phosphorothioate oligonucleotide for the treatment of CMV retinitis. Ocul Immunol Inflamm 1999; 7: 189-198.
43. Stone TW, Jaffe GJ: Reversible bull s-eye maculopathy associated with intravitreal fomivirsen therapy for cytomegalovirus retinitis. Am J Ophthalmol 2000; 130: 242-243.
44. Amin HI, Ai E, McDonald HR, Johnson RN: Retinal toxic effects associated with intravitreal fomivirsen. Arch Ophthalmol 2000; 118: 426-427.
45. Uwaydat SH, Li HK: Pigmentary retinopathy associated with intravitreal fomivirsen. Arch Ophthalmol 2002; 120: 854-857.
46. Besen G, Chavez-de la Paz E, Tatebayashi M, Flores-Aguilar M, Gangan PA, Munguia D, Wiley CA, Jahne G, Winkler I, Helsberg M, et al: Evaluation of retinal toxicity and efficacy of the anticytomegalovirus compound 2-amino-7-[(1,3-dihydroxy-2-propoxy) methyl]purine. Antimicrob Agents Chemother 1995; 39: 1485-1488.
47. Besen G, Flores-Aguilar M, Assil KK, Kupperman BD, Gangan P, Pursley M, Munguia D, Vuong C, De Clercq E, Bergeron-Lynn G, et al: Long-term therapy for herpes retinitis in an animal model with high-concentrated liposome-encapsulated HPMPC. Arch Ophthalmol 1995; 113: 661-668.
48. Dolnak DR, Munguia D, Wiley CA, De Clercq E, Bergeron-Lynn GL, Boscher C, Connor JD, Sherwood C, Capparelli E, Armani R, et al: Lack of retinal toxicity of the anticytomegalovirus drug (S)-1-(3-hydroxy- 2-phosphonylmethoxypropyl) cytosine. Invest Ophthalmol Vis Sci 1992; 33: 1557-1563.
49. Flores-Aguilar M, Huang JS, Wiley CA, De Clercq E, Vuong C, Bergeron-Lynn G, Chandler B, Munguia D, Freeman WR: Long-acting therapy of viral retinitis with (S)-1-(3-hydroxy- 2-phosphonylmethoxypropyl)cytosine. J Infect Dis 1994; 169: 642-647.
50. Kuppermann BD, Assil KK, Vuong C, Besen G, Wiley CA, De Clercq E, Bergeron-Lynn G, Connor JD, Pursley M, Munguia D, Freeman WR: Liposome-encapsulated (S)-1-(3-hydroxy- 2-phosphonylmethoxypropyl)cytosine for long-acting therapy of viral retinitis. J Infect Dis 1996; 173: 18-23.
51. Kirsch LS, Arevalo JF, Chavez de la Paz E, Munguia D, de Clercq E, Freeman WR: Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophthalmology 1995; 102: 533-542, discussion 542-533.
52. Kirsch LS, Arevalo JF, De Clercq E, Chavez de la Paz E, Munguia D, Garcia R, Freeman WR: Phase I/II study of intravitreal cidofovir for the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol 1995; 119: 466-476.
53. Tammewar AM, Cheng L, Hostetler KY, Falkenstein I, Beadle JR, Barron EC, Kozak I, Freeman WR: Intraocular properties of an alkoxyalkyl derivative of cyclic 9-(S)-(3-hydroxyl- 2-phosphonomethoxypropyl)adenine, an intravitreally injectable anti-HCMV drug in rabbit and guinea pig. J Ocul Pharmacol Ther 2007; 23: 433-444.
54. Blumenkranz M, Hernandez E, Ophir A, Norton EW: 5-Fluorouracil: new applications in complicated retinal detachment for an established antimetabolite. Ophthalmology 1984; 91: 122-130.
55. Kummar S, Gutierrez M, Doroshow JH, Murgo AJ: Drug development in oncology: classical cytotoxics and molecularly targeted agents. Br J Clin Pharmacol 2006; 62: 15-26. (Pubitemid 44195239)
56. Peyman GA, Greenberg D, Fishman GA, Fiscella R, Thomas A: Evaluation of toxicity of intravitreal antineoplastic drugs. Ophthalmic Surg 1984; 15: 411-413.
57. Yoshizumi MO, Silverman C: Experimental intravitreal 5-fluorocytosine. Ann Ophthalmol 1985; 17: 58-61.
58. Barrada A, Peyman GA, Case J, Fishman G, Thomas A, Fiscella R: Evaluation of intravitreal 5-fluorouracil, vincristine, VP 16, doxorubicin, and thiotepa in primate eyes. Ophthalmic Surg 1984; 15: 767-769.
59. Leon JA, Britt JM, Hopp RH, Mills RP, Milam AH: Effects of fluorouracil and fluorouridine on protein synthesis in rabbit retina. Invest Ophthalmol Vis Sci 1990; 31: 1709-1716.
60. Kivilcim M, Kazi AA, Peyman GA, Hegazy H, El Dessouky S, Cheema R, Laghari NA: Retinal toxicity of intravitreal 5-fluorouracil in silicone-filled rabbit eyes. J Coll Physicians Surg Pak 2006; 16: 351-354.
61. Cardillo JA, Farah ME, Mitre J, Morales PH, Costa RA, Melo LA, Kuppermann B, Jorge R, Ashton P: An intravitreal biodegradable sustained release naproxen and 5-fluorouracil system for the treatment of experimental post-traumatic proliferative vitreoretinopathy. Br J Ophthalmol 2004; 88: 1201-1205.
62. Joondeph BC, Peyman GA, Khoobehi B, Yue BY: Liposome-encapsulated 5-fluorouracil in the treatment of proliferative vitreoretinopathy. Ophthalmic Surg 1988; 19: 252-256.
63. Macky TA, Oelkers C, Rix U, Heredia ML, Kunzel E, Wimberly M, Rohrer B, Crosson CE, Rohr J: Synthesis, pharmacokinetics, efficacy, and rat retinal toxicity of a novel mitomycin C-triamcinolone acetonide conjugate. J Med Chem 2002; 45: 1122-1127.
64. Kawashima S, Mizota A, Adachi-Usami E, Kimura T: Effects of mitomycin C on the rat retina. Doc Ophthalmol 1996; 92: 229-241.
65. Velez G, Yuan P, Sung C, Tansey G, Reed GF, Chan CC, Nussenblatt RB, Robinson MR: Pharmacokinetics and toxicity of intravitreal chemotherapy for primary intraocular lymphoma. Arch Ophthalmol 2001; 119: 1518-1524.
66. Yu HG, Chung H: Antiproliferative effect of mitomycin C on experimental proliferative vitreoretinopathy in rabbits. Korean J Ophthalmol 1997; 11: 98-105.
67. Huna R, Moisseiev J, Dany S, Ezra D: Lack of intravitreal penetration of colchicine after oral administration in rabbits. Retina 1996; 16: 259-261.
68. Davidson C, Green WR, Wong VG: Retinal atrophy induced by intravitreous colchicine. Invest Ophthalmol Vis Sci 1983; 24: 301-311.
69. Fishburne BC, Wilson DJ, Rosenbaum JT, Neuwelt EA: Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Arch Ophthalmol 1997; 115: 1152-1156.
70. Smith JR, Rosenbaum JT, Wilson DJ, Doolittle ND, Siegal T, Neuwelt EA, Pe er J: Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 2002; 109: 1709-1716.
71. Vernot J, Peyman GA, Gailitis R, Fiscella R, Woodhouse M, Weinberg D: Effects of selected repeated intravitreal chemotherapeutic agents. Int Ophthalmol 1985; 8: 193-198.
72. Sou R, Ohguro N, Maeda T, Saishin Y, Tano Y: Treatment of primary intraocular lymphoma with intravitreal methotrexate. Jpn J Ophthalmol 2008; 52: 167-174.
73. Hardwig PW, Pulido JS, Erie JC, Baratz KH, Buettner H: Intraocular methotrexate in ocular diseases other than primary central nervous system lymphoma. Am J Ophthalmol 2006; 142: 883-885.
74. Cai J, Wei R, Ma X, Zhu H, Li Y: Cytotoxic effects of antiproliferative agents on human retinal glial cells in vitro. Int Ophthalmol 2001; 24: 225-231.
75. Hardwig PW, Pulido JS, Bakri SJ: The safety of intraocular methotrexate in silicone-filled eyes. Retina 2008; 28: 1082-1086.
76. Ueda M, Tanabe J, Inomata M, Kaneko A, Kimura T: Study on conservative treatment of retinoblastoma - effect of intravitreal injection of melphalan on the rabbit retina. Nippon Ganka Gakkai Zasshi 1995; 99: 1230-1235.
77. Yamane T, Kaneko A, Mohri M: The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma. Int J Clin Oncol 2004; 9: 69-73.
78. Shimoda Y, Hamano R, Ishihara K, Shimoda N, Hagimura N, Akiyama H, Kishi S, Kaneko A: Effects of intraocular irrigation with melphalan on rabbit retinas during vitrectomy. Graefes Arch Clin Exp Ophthalmol 2008; 246: 501-508.
79. Kaneko A, Suzuki S: Eye-preservation treatment of retinoblastoma with vitreous seeding. Jpn J Clin Oncol 2003; 33: 601-607.
80. Abramson DH, Dunkel IJ, Brodie SE, Kim JW, Gobin YP: A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma: initial results. Ophthalmology 2008; 115: 1398-1404.
81. Iriyama A, Chen YN, Tamaki Y, Yanagi Y: Effect of anti-VEGF antibody on retinal ganglion cells in rats. Br J Ophthalmol 2007; 91: 1230-1233.
82. Luke M, Warga M, Ziemssen F, Gelisken F, Grisanti S, Schneider T, Luke C, Partsch M, Bartz-Schmidt KU, Szurman P: Effects of bevacizumab on retinal function in isolated vertebrate retina. Br J Ophthalmol 2006; 90: 1178-1182.
83. Luthra S, Narayanan R, Marques LE, Chwa M, Kim DW, Dong J, Seigel GM, Neekhra A, Gramajo AL, Brown DJ, Kenney MC, Kuppermann BD: Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina 2006; 26: 512-518.
84. Bakri SJ, Cameron JD, McCannel CA, Pulido JS, Marler RJ: Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am J Ophthalmol 2006; 142: 162-164.
85. Heiduschka P, Fietz H, Hofmeister S, Schultheiss S, Mack AF, Peters S, Ziemssen F, Niggemann B, Julien S, Bartz-Schmidt KU, Schraermeyer U: Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007; 48: 2814-2823.
86. Kaempf S, Johnen S, Salz AK, Weinberger AW, Walter P, Thumann G: Effects of bevacizumab (Avastin) on retinal cells in organotypic culture. Invest Ophthalmol Vis Sci 2008; 49: 3164-3171.
87. Inan UU, Avci B, Kusbeci T, Kaderli B, Avci R, Temel SG: Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci 2007; 48: 1773-1781.
88. Manzano RP, Peyman GA, Khan P, Kivilcim M: Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006; 26: 257-261.
89. Shahar J, Avery RL, Heilweil G, Barak A, Zemel E, Lewis GP, Johnson PT, Fisher SK, Perlman I, Loewenstein A: Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006; 26: 262-269.
90. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V: Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005; 46: 726-733.
91. Peters S, Heiduschka P, Julien S, Ziemssen F, Fietz H, Bartz-Schmidt KU, Schraermeyer U: Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 2007; 143: 995-1002.
92. Chan CK, Lin SG: Retinal pigment epithelial tear after ranibizumab therapy for subfoveal fibrovascular pigment epithelial detachment. Eur J Ophthalmol 2007; 17: 674-676.
93. Rodrigues EB, Shiroma H, Meyer CH, Maia M, Farah ME: Metrorrhagia after intravitreal injection of bevacizumab. Acta Ophthalmol Scand 2007; 85: 915-916.
94. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, Miller JW, Haller JA, Reimann JD, Greene WL, Shams N: Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 2005; 112: 1048-1053.
95. Rosenfeld PJ: Intravitreal Avastin: the low cost alternative to Lucentis? Am J Ophthalmol 2006; 142: 141-143.
96. Rosenfeld PJ: New treatments for age-related macular degeneration. Lancet 2007; 370: 1479, author reply 1480.
97. Dick AD, Forrester JV, Liversidge J, Cope AP: The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). Prog Retin Eye Res 2004; 23: 617-637.
98. Imrie FR, Dick AD: Biologics in the treatment of uveitis. Curr Opin Ophthalmol 2007; 18: 481-486.
99. Giansanti F, Ramazzotti M, Vannozzi L, Rapizzi E, Fiore T, Iaccheri B, Degl Innocenti D, Moncini D, Menchini U: A pilot study on ocular safety of intravitreal infliximab in a rabbit model. Invest Ophthalmol Vis Sci 2008; 49: 1151-1156.
100. Fauser S, Kalbacher H, Alteheld N, Koizumi K, Krohne TU, Joussen AM: Pharmacokinetics and safety of intravitreally delivered etanercept. Graefes Arch Clin Exp Ophthalmol 2004; 242: 582-586.
101. Kivilcim M, Peyman GA, Kazi AA, Dellacroce J, Ghobrial RN, Monzano R: Intravitreal toxicity of high-dose etanercept. J Ocul Pharmacol Ther 2007; 23: 57-62.
102. Manzano RP, Peyman GA, Carvounis PE, Kivilcim M, Khan P, Chevez-Barrios P, Takahashi W: Ocular toxicity of intravitreous adalimumab (Humira) in the rabbit. Graefes Arch Clin Exp Ophthalmol 2008; 246: 907-911.
103. Lim L, Suhler EB, Smith JR: Biologic therapies for inflammatory eye disease. Clin Exp Ophthalmol 2006; 34: 365-374.
104. Suhler EB, Smith JR, Wertheim MS, Lauer AK, Kurz DE, Pickard TD, Rosenbaum JT: A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005; 123: 903-912.
105. Theodossiadis PG, Markomichelakis NN, Sfikakis PP: Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina 2007; 27: 399-413.
106. Coiffier B: Rituximab therapy in malignant lymphoma. Oncogene 2007; 26: 3603-3613.
107. Kim H, Csaky KG, Chan CC, Bungay PM, Lutz RJ, Dedrick RL, Yuan P, Rosenberg J, Grillo-Lopez AJ, Wilson WH, Robinson MR: The pharmacokinetics of rituximab following an intravitreal injection. Exp Eye Res 2006; 82: 760-766.
108. Kitzmann AS, Pulido JS, Mohney BG, Baratz KH, Grube T, Marler RJ, Donaldson MJ, O Neill BP, Johnston PB, Johnson KM, Dixon LE, Salomao DR, Cameron JD: Intraocular use of rituximab. Eye 2007; 21: 1524-1527.
109. Kim SJ, Adams NA, Toma HS, Belair ML, Thorne JE, Green WR, Jabs DA: Safety of intravitreal ketorolac and diclofenac: an electroretinographic and histopathologic study. Retina 2008; 28: 595-605.
110. Komarowska I, Heilweil G, Rosenfeld PJ, Perlman I, Loewenstein A: Retinal toxicity of commercially available intravitreal ketorolac in albino rabbits. Retina 2009; 29: 98-105.
111. Morales AM, Kivilcim M, Peyman GA, Main M, Manzano RP: Intravitreal toxicity of ketorolac Tris salt and flurbiprofen. Ophthalmic Surg Lasers Imaging 2009; 40: 38-42.
112. Trese MT: Enzymatic-assisted vitrectomy. Eye 2002; 16: 365-368.
113. Textorius O, Stenkula S: Toxic ocular effects of two fibrinolytic drugs: an experimental electroretinographic study on albino rabbits. Acta Ophthalmol (Copenh) 1983; 61: 322-331.
114. De Smet MD, Valmaggia C, Zarranz-Ventura J, Willekens B: Microplasmin: ex vivo characterization of its activity in porcine vitreous. Invest Ophthalmol Vis Sci 2009; 50: 814-819.
115. Wang ZL, Shi WD, Luo M, Bi XP, Ji J: Pharmacologic vitreolysis with plasmin and hyaluronidase in diabetic rats. Retina 2009; 29: 269-274.
116. Frenkel S, Hendler K, Siegal T, Shalom E, Pe er J: Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. Br J Ophthalmol 2008; 92: 383-388.
117. Srinivasan K, Ramarao P: Animal models in type 2 diabetes research: an overview. Indian J Med Res 2007; 125: 451-472.
118. Danis RP, Ciulla TA, Pratt LM, Anliker W: Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000; 20: 244-250.
119. Jonas JB, Kreissig I, Degenring RF: Intravitreal triamcinolone acetonide as treatment of ischemic ophthalmopathy. Eur J Ophthalmol 2003; 13: 575-576. (Pubitemid 38208842)
120. Jonas JB, Kreissig I, Degenring RF: Intravitreal triamcinolone acetonide for pseudophakic cystoid macular edema. Am J Ophthalmol 2003; 136: 384-386. (Pubitemid 36904101)
121. Jonas JB, Kreissig I, Degenring RF: Retinal complications of intravitreal injections of triamcinolone acetonide. Graefes Arch Clin Exp Ophthalmol 2004; 242: 184-185. (Pubitemid 38324974)
122. Ranson NT, Danis RP, Ciulla TA, Pratt L: Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration. Br J Ophthalmol 2002; 86: 527-529.
123. Avci R, Kaderli B: Intravitreal triamcinolone injection for chronic diabetic macular oedema with severe hard exudates. Graefes Arch Clin Exp Ophthalmol 2006; 244: 28-35. (Pubitemid 43013179)
124. Gibran SK, Cullinane A, Jungkim S, Cleary PE: Intravitreal triamcinolone for diffuse diabetic macular oedema. Eye 2006; 20: 720-724.
125. Jonas JB, Hayler JK, Sofker A, Panda-Jonas S: Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2001; 131: 468-471. (Pubitemid 32273433)
126. Williamson TH, O Donnell A: Intravitreal triamcinolone acetonide for cystoid macular edema in nonischemic central retinal vein occlusion. Am J Ophthalmol 2005; 139: 860-866.
127. Lee H, Shah GK: Intravitreal triamcinolone as primary treatment of cystoid macular edema secondary to branch retinal vein occlusion. Retina 2005; 25: 551-555.
128. Wang K, Jiang YR, Li XX: Vehicle of triamcinolone acetonide is associated with retinal toxicity and transient increase of lens density. Graefes Arch Clin Exp Ophthalmol 2006; 244: 1152-1159.
129. Lang Y, Leibu R, Shoham N, Miller B, Perlman I: Evaluation of intravitreal Kenalog toxicity in humans. Ophthalmology 2007; 114: 724-731. (Pubitemid 46483697)
130. Li Q, Wang J, Yang L, Mo B, Zeng H, Wang N, Liu W: A morphologic study of retinal toxicity induced by triamcinolone acetonide vehicles in rabbit eyes. Retina 2008; 28: 504-510.
131. Macky TA, Helmy D, El Shazly N: Retinal toxicity of triamcinolone s vehicle (benzyl alcohol): an electrophysiologic and electron microscopic study. Graefes Arch Clin Exp Ophthalmol 2007; 245: 817-824.
132. Rodriguez-Coleman H, Yuan P, Kim H, Gravlin L, Srivastava S, Csaky KG, Robinson MR: Intravitreal injection of triamcinolone for diffuse macular edema. Arch Ophthalmol 2004; 122: 1085-1086, author reply 1086-1088.
133. Lang Y, Zemel E, Miller B, Perlman I: Retinal toxicity of intravitreal Kenalog in albino rabbits. Retina 2007; 27: 778-788. (Pubitemid 47051776)
134. Li Q, Wang J, Yang L, Mo B, Zeng H, Wang N, Liu W: A morphologic study of retinal toxicity induced by triamcinolone acetonide vehicles in rabbit eyes. Retina 2008; 28: 504-510.
135. Loewenstein A, Zemel E, Lazar M, Perlman I: The effects of Depo-Medrol preservative on the rabbit visual system. Invest Ophthalmol Vis Sci 1991; 32: 3053-3060.
136. Luke M, Januschowski K, Warga M, Beutel J, Leitritz M, Gelisken F, Grisanti S, Schneider T, Luke C, Bartz-Schmidt KU, Szurman P: The retinal tolerance to bevacizumab in co-application with a recombinant tissue plasminogen activator. Br J Ophthalmol 2007; 91: 1077-1082.
137. Loewenstein A, Zemel E, Lazar M, Perlman I: Drug-induced retinal toxicity in albino rabbits: the effects of imipenem and aztreonam. Invest Ophthalmol Vis Sci 1993; 34: 3466-3476.
138. Rowley SA, Vijayasekaran S, Yu PK, McAllister IL, Yu DY: Retinal toxicity of intravitreal tenecteplase in the rabbit. Br J Ophthalmol 2004; 88: 573-578.
139. Frambach DA, Marmor MF: The rate and route of fluid resorption from the subretinal space of the rabbit. Invest Ophthalmol Vis Sci 1982; 22: 292-302.
140. Ivert L, Kjeldbye H, Gouras P: Long-term effects of short-term retinal bleb detachments in rabbits. Graefes Arch Clin Exp Ophthalmol 2002; 240: 232-237.
141. Negi A, Marmor MF: Effects of subretinal and systemic osmolality on the rate of subretinal fluid resorption. Invest Ophthalmol Vis Sci 1984; 25: 616-620. (Pubitemid 14149158)
142. Negi A, Marmor MF: Experimental serous retinal detachment and focal pigment epithelial damage. Arch Ophthalmol 1984; 102: 445-449.
143. Negi A, White MP, Marmor MF: Effects of hemicholinium-3, a photoreceptor and pigment epithelial toxin, on retinal adhesiveness and subretinal fluid absorption. Doc Ophthalmol 1993; 83: 331-336.
144. Ho JD, Tsai RJ, Chen SN, Chen HC: Cytotoxicity of indocyanine green on retinal pigment epithelium: implications for macular hole surgery. Arch Ophthalmol 2003; 121: 1423-1429.
145. Ikagawa H, Yoneda M, Iwaki M, Isogai Z, Tsujii K, Yamazaki R, Kamiya T, Zako M: Chemical toxicity of indocyanine green damages retinal pigment epithelium. Invest Ophthalmol Vis Sci 2005; 46: 2531-2539.
146. Sippy BD, Engelbrecht NE, Hubbard GB, Moriarty SE, Jiang S, Aaberg TM Jr, Aaberg TM Sr, Grossniklaus HE, Sternberg P Jr: Indocyanine green effect on cultured human retinal pigment epithelial cells: implication for macular hole surgery. Am J Ophthalmol 2001; 132: 433-435.